| Objective: To observe and evaluate the clinical efficacy of late cancer prescription combined with low-dose Apatinib + Teggio in the treatment of advanced gastric cancer patients with poor chemotherapy tolerance,and to provide certain clinical basis for the combined treatment of advanced gastric cancer patients with Chinese and western chemotherapy.Methods: A prospective randomized control was used.According to inclusion and exclusion criteria,60 patients were numbered according to the time of admission,and were randomly assigned to the control group and the observation group by completely random number table method.The control group was given an oral dose of Teggio +Apatinib mesylate.The dosage of the former was 20mg/time,twice a day,about 30 min after meals,and 3 weeks was taken as a course of treatment,the interval of treatment was one week.Apatinib mesylate 125 mg,once before bed every night,consecutive daily.On the basis of the control group,the treatment group was given evening cancer prescription orally every day,1 dose a day,30 minutes after breakfast and dinner.The control group and the observation group were treated for 28 days as a course of treatment.After 2 courses of treatment,the clinical efficacy of the two groups were observed,and the immune function,serum tumor marker level,KPS function status score,blood routine detection,TCM syndrome score evaluation,as well as the occurrence of hypertension,abnormal liver function,fatigue,albuminuria,nausea and other adverse reactions were observed.Results: 60 patients who met the inclusion criteria were divided into control group(30cases)(Ticeo + Apatinib mesylate)and treatment group(30 cases)(late cancer prescription plus or minus combined with low-dose ticeo + Apatinib mesylate).There were no discontinuation or abatinib patients in this study.The distribution of patients was evaluated,and the age of the two groups was 67.60±8.61 years old in the control group and 66.23±10.06 years old in the treatment group.There was no significant difference in the age of the two groups.In terms of pathological classification,there were more adenocarcinoma patients in both groups.In the study of short-term efficacy,ORR and DCR were 20% and 56.67.3% in the control group.ORR(23.3%)and DCR(63.33%)in treatment group;There were no significant differences in ORR and DCR between the two groups.In the recent KPS score study,KPS score of the treatment group was statistically significant compared with that of this group before and after treatment(P < 0.05),and KPS score of the treatment group and control group was statistically significant after treatment(P < 0.05).In the treatment level of tumor markers,CEA level was different between the two groups(P < 0.05).The levels of CA199,CEA and CA724 were different between control group and treatment group before and after treatment(P < 0.05).In terms of the levels of WBC,HGB and PLT between the two groups,the levels of WBC and PLT in the treatment group before and after treatment were statistically significant(P < 0.05),while the levels of PLT,HGB and WBC in the control group were different before and after treatment(P < 0.05).In comparison of IgM,IgA and IgG levels,there were differences between the two groups before and after treatment(P < 0.05).In TCM syndrome score evaluation,there was statistical significance between the two groups before and after treatment(P < 0.05);The TCM syndrome scores of abdominal distension,poor appetite,fatigue and loose stool in the treatment group were statistically significant compared with the control group(P <0.05).In addition,the total effective rate of the control group was 56.67% in the evaluation of TCM efficacy of the two groups.The total effective rate of the treatment group was 86.67%,and the difference was statistically significant(P < 0.05).In terms of adverse reactions,the incidence of hypertension,diarrhea and albuminuria in the control group was significantly higher than that in the treatment group,and the difference was significant(P < 0.05).Conclusion: Late cancer prescription combined with low dose Apatinib + Tiggio in the treatment of advanced gastric cancer that could not tolerate conventional chemotherapy In the clinical treatment of patients,it can significantly reduce clinical symptoms,relieve patients’ pain,improve patients’ immune function benefits,improve TCM syndrome scores,and reduce the toxic and side effects of modern medical treatment such as radiotherapy and chemotherapy,which has outstanding clinical practical significance and development prospects. |
PDF Full Text Request